Nov 29, 2018 2:50 pm EST Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
Nov 19, 2018 8:30 am EST Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
Nov 06, 2018 7:30 am EST Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
Nov 01, 2018 9:03 am EDT Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018
Sep 24, 2018 4:55 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 11, 2018 8:00 am EDT Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
Sep 06, 2018 7:30 am EDT Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Aug 06, 2018 4:50 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)